Sai Parenterals Ltd (SAIPARENT)
🎯 Key Takeaways
- Revenue declined 9.7% QoQ to ₹179 in Q1FY27.
- Market Cap
- ₹2,336
- P/E Ratio
- 142.9
- P/B Ratio
- 4.76
- ROE
- 3.2%
- ROCE
- 4.6%
- Debt/Equity
- 0.68
- Promoter
- 51.2%
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 33 | 96 | 198 | 179 |
| Operating Profit | 3 | -9 | 18 | 15 |
| OPM % | 9.9% | -9.7% | 9.1% | 8.6% |
| Net Profit | 1 | -7 | 13 | 8 |
| EPS | ₹0.11 | ₹-2.22 | ₹4.02 | ₹1.79 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 13 | 22 | 18 |
| Reserves | 80 | 469 | 189 |
| Borrowings | 94 | 333 | 78 |
| Total Liabilities | 272 | 1,424 | 288 |
| Fixed Assets | 53 | 191 | 47 |
| Investments | 0 | 0 | 0 |
| Total Assets | 272 | 1,424 | 288 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +33 |
| Investing | +0 |
| Financing | -36 |
| Net Cash Flow | -2 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 61.2% | 51.2% | 51.2% |
| FII | 0.0% | 5.7% | 4.0% |
| DII | 0.0% | 12.9% | 8.5% |
| Public | 0.0% | 22.7% | 25.3% |
| # Shareholders | 119 | 7,687 | 9,312 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Announcement2026-10-01Sai Parenterals Ltd announced a scheduled investor and analyst meeting in Hyderabad on October 14, 2026, to discuss publicly available information, wi…
- 🟡 Board Meeting2026-09-30Sai Parenterals announced board approval of Ms. Shivali Aggarwal's resignation as Company Secretary and Compliance Officer effective 30 September 2026…
- Announcement2026-09-30Sai Parenterals Ltd announced that its trading window will close on 1 October 2026 and remain shut until 48 hours after the un-audited Q3 results are …
- 🟡 Board Meeting2026-09-30Sai Parenterals announced board approval of Ms. Shivali Aggarwal's resignation effective 30 September 2026 and appointed Mr. Ashwani Singh Bisht as ne…
- 🟡 Board Meeting2026-09-10Sai Parenterals held its 25th Annual General Meeting on 10 September 2026 via video conference, approving the audited financial statements, reappointi…
- 🟡 voting results2026-09-10Sai Parenterals held its AGM on 10 September 2026 via video conference, approving all 12 proposed resolutions with majority support. The audited finan…
- 🟡 Board Meeting2026-08-19Sai Parenterals Limited announced that its 25th Annual General Meeting will be held on 10 September 2026 at 11:00 a.m. IST via video conference, with …
- 🔴 annual report2026-08-19Sai Parenterals Limited (NSE: SAIPARENT) announced its 25th AGM scheduled for 10 September 2026 via video conference, with shareholders approving key …
- 🔴 Financial Results2026-08-18Sai Parenterals reported consolidated revenue of **₹182 crores** in Q1 FY27, up from Rs. 56 crores standalone, with gross margin expanding to 41.8% an…
- 🔴 Financial Results2026-08-12Sai Parenterals Limited reported FY26 revenue of [amount context mismatch] crore with a 17% EBITDA margin target for FY27, driven by export revenue ri…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SAIPARENT files new disclosures
Track SAIPARENT filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SAIPARENT — FreeFree account · 2 AI queries/day